Heron Therapeutics (HRTX) Announces HTX-011 Phase 2 Met Primary, Secondary Endpoints in Post-Operative Pain
Tweet Send to a Friend
Heron Therapeutics (NASDAQ: HRTX) announced positive, top-line results from its Phase 2 clinical study of HTX-011 in the management of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
